Thrombin activatable fibrinolysis inhibitor promotes development of chronic thromboembolic pulmonary hypertension -A possible novel therapeutic target-
Event:
ESC Congress 2017
Topic:
Chronic pulmonary hypertension
Session:
Young Investigator Awards Session Basic Science